PAD Interventional Market Analysis Based on Treatment with
Angioplasty or Atherectomy

This report analyzes historical (1997-2008) interventional procedures employed to treat lower limb arterial disease, as well as projects revascularization procedures for the 2008-2020 periods.

Procedures include revascularization with surgery or endovascular devices, as well as amputation.

Employing ICD-9 procedure data, PAD Interventional Market Analysis Based on Treatment with Angioplasty or Atherectomy provides a comprehensive examination of the following topics: an overview of the 2008 inpatient interventional market by type of procedure and vascular territory; an in-depth analysis of 2008 revascularization procedures considered suitable for treatment with angioplasty or atherectomy in the aortoiliac, femoropopliteal and tibioperoneal regions; an examination of amputation by type of procedure and territory; an analysis of inpatient and outpatient endovascular procedures by type and vascular territory and forecasts of endovascular procedures through 2020 by device type and territory.

Because primary stents are considered to be an alternative to angioplasty or atherectomy, the endovascular market analyses are based on primary stents only. For comparative purposes, overviews of the endovascular market including provisional stents and the interventional market with provisional stents by type of procedure are included. In addition an analysis of inpatient primary and provisional stenting by type and territory is provided.    

The report provides extensive data, including the estimated number of people in the U.S. with PAD in the 2005-2020 periods and the U.S. PAD revascularization market for surgical and endovascular procedures in the 2005-2020 periods.

Based on two alternative technological scenarios, angioplasty/atherectomy and primary stent procedures are projected from 2008 through 2020 in the aortoiliac, femoropopliteal and tibioperoneal vascular regions. The optimistic case reflects primary stenting gaining share, while in the pessimistic case primary stenting loses share.

The dollar value of the current endovascular device market is also evaluated, featuring a comparison of size and share by device type in 1997 and 2008.

Price: $2,900 (Single User License) $4,400 (Corporate License)

Contact witherspoon@thesagegroup.us

To purchase call us at 404 816-0746

Table of Contents

Index of Tables and Figures

References

Sample Pages
[Available on Request]